Citations Appearing in 2012

  1. Abdelraouf, K., J. He, K.R. Ledesma, M. Hu and V.H. Tam. Pharmacokinetics and renal disposition of polymyxin B in an animal model. Antimicrobial Agents and Chemotherapy 56(11):5724-5727, 2012.
  2. Adane, E., Z. Liu, T.-X. Xiang, B. Anderson, M. Leggas. Pharmacokinetic modeling to assess factors affecting the oral bioavailability of the lactone and carboxylate forms of the lipophilic camptothecin analogue AR-67 in rats. Pharmaceutical Research 29(7):1722-1736, 2012.
  3. Al-Nakeeb, Z., A. Sudan, A.R. Jeans, L. Gregson, J. Goodwin, P.A. Warn, . . .and W.W. Hope. Pharmacodynamics of itraconazole against aspergillus fumigatus in an in vitro model of the human alveolus: perspectives on the treatment of triazole-resistant infection and utility of airway administration. Antimicrobial Agents and Chemotherapy 56(8):4146-4153, 2012.
  4. An, G., and M. Morris. A ahysiologically based pharmacokinetic model of mitoxantrone in mice and scale-up to humans: a semi-mechanistic model incorporating DNA and protein binding. The AAPS Journal 14(2):352-364, 2012.
  5. Arendrup, M.C., D.S. Perlin, R.H. Jensen, S.J. Howard, J. Goodwin, H. William. Differential in vivo activities of anidulafungin, caspofungin, and micafungin against candida glabrata isolates with and without FKS resistance mutations. Antimicrobial Agents and Chemotherapy 56(5):2435-2442, 2012.
  6. Barau, C., V. Furlan, D. Debray, A.-M. Taburet, and A. Barrail-Tran. Population pharmacokinetics of mycophenolic acid and dose optimisation with limited sampling strategy in liver transplant children. British Journal of Clinical Pharmacology 74(3):515-524, 2012.
  7. Beringer, P.M., H. Owens, A. Nguyen, D. Benitez, A. Rao, and D.Z. D’Argenio. Pharmacokinetics of doxycycline in adults with cystic fibrosis. Antimicrobial Agents and Chemotherapy 56(1):70-74, 2012.
  8. Bertera, F. Enantioselective pharmacokinetic and pharmacodynamic properties of carvedilol in spontaneously hypertensive rats: focus on blood pressure variability. Naunyn-Schmiedeberg’s Archives of Pharmacology 385(3):1-11, 2012.
  9. Bertera, F. Pharmacokinetic and pharmacodynamic properties of carvedilol in fructose hypertensive rats. Xenobiotica 42(2):206-219, 2012.
  10. Beumer, J.H., R.A. Parise, B. Kanterewicz, M. Petkovich, D.Z. D’Argenio. A local effect of CYP24 inhibition on lung tumor xenograft exposure to 1,25-dihydroxyvitamin D3 is revealed using a novel LC-MS/MS assay. Steroids 77(5):477-483, 2012.
  11. Bouzom, F., K. Ball, N. Perdaems, B. Walther. Physiologically based pharmacokinetic (PBPK) modelling tools: how to fit with our needs? Biopharmaceutics & Drug Disposition 33(2):55-71, 2012.
  12. Brown, A.N., J.J. McSharry, J.R. Adams, R. Kulawy, R.J.O. Barnard, W. Newhard, . . .and G.L. Drusano. Pharmacodynamic analysis of a serine protease inhibitor, MK-4519, against hepatitis C virus using a novel in vitro pharmacodynamic system. Antimicrobial Agents and Chemotherapy 56(3):1170-1181, 2012.
  13. Brown, J., K. Brown, A. Forrest. Vancomycin AUC24/MIC in MRSA complicated bacteremia and infective endocarditis patients and its association with attributable mortality during hospitalization. Antimicrobial Agents and Chemotherapy 56(2):634-638, 2012.
  14. Cao, Y., D.C. DuBois, R.R. Almon, and W.J. Jusko. Pharmacokinetics of salsalate and salicylic acid in normal and diabetic rats. Biopharmaceutics and Drug Disposition 33(6):285-291, 2012.
  15. Cao, Y., W. Gao and W. Jusko. Pharmacokinetic/pharmacodynamic modeling of GLP-1 in healthy rats. Pharmaceutical Research 29(4):1078-1086, 2012.
  16. Cardone, K., D.W. Grabe, R W. Kulawy, R. Daoui, J. Roglieri, S. Meola, G L. Drusano, and T P. Lodise. Ertapenem pharmacokinetics and pharmacodynamics during continuous ambulatory peritoneal dialysis. Antimicrobial Agents and Chemotherapy 56(2):725-730, 2012.
  17. Chae, J.-w., I.-h. Baek, B.-y. Lee, S.-k. Cho, and K.-i. Kwon. Population PK/PD analysis of metformin using the signal transduction model. British Journal of Clinical Pharmacology 74(5):815-823, 2012.
  18. Chen, S.-H., C.-P. Yang, T.-H. Jaing, I.-J. Hung, L.-Y. Shih, P.-C. Ho,… and J.-L. Huang. Clinical impact of in vitro cellular drug resistance on childhood acute lymphoblastic leukemia in Taiwan. Leukemia and Lymphoma 53(8):1536-1542, 2012.
  19. Choo, E., C. Ng, L. Berry, M. Belvin, N. Lewin-Koh, M. Merchant and L. Salphati. PK-PD modeling of combination efficacy effect from administration of the MEK inhibitor GDC-0973 and PI3K inhibitor GDC-0941 in A2058 xenografts. Cancer Chemotherapy and Pharmacology 71(0):133-143, 2012.
  20. Chudasama, V.L., F. Schaedeli Stark, J.M. Harrold, J. Tibbitts, S.R. Girish, M. Gupta, . . .and D.E. Mager. Semi-mechanistic population pharmacokinetic model of multivalent trastuzumab emtansine in patients with metastatic breast cancer. Clinical Pharmacology Therapeutics 92(4):520-527, 2012.
  21. Dette, H., A. Pepelyshev and W. Wong. Optimal designs for composed models in pharmacokinetic–pharmacodynamic experiments. Journal of Pharmacokinetics and Pharmacodynamics 39(3):295-311, 2012.
  22. Drusano, G.L. Resistance emergence mechanism and mechanism of resistance suppression by tobramycin for cefepime for pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy 56(1):231-242, 2012.
  23. Dumond, J., M. Nicol, R. Kendrick, S. Garonzik, K. Patterson, M. Cohen, . . .and A.M. Kashuba. Pharmacokinetic Modelling of Efavirenz, Atazanavir, Lamivudine and Tenofovir in the Female Genital Tract of HIV-Infected Pre-Menopausal Women. Clinical Pharmacokinetics 51(12): 809-822, 2012.
  24. Felton, T.W., W.W. Hope, B.M. Lomaestro, J.M. Butterfield, A.L. Kwa, G.L. Drusano, T.P. Lodise. Population pharmacokinetics of extended infusion piperacillin/tazobactam in hospitalized patients with nosocomial infections. Antimicrobial Agents and Chemotherapy 56(8):4087-4094, 2012.
  25. Fischer, J.H., G.E. Sarto, M. Habibi, S.J. Kilpatrick, R.E. Tuomala, J.M. Shier, . . . and K.A. Rodvold. Influence of body weight, ethnicity, oral contraceptives and pregnancy on the pharmacokinetics of azithromycin in women of child-bearing age. Antimicrobial Agents and Chemotherapy 56(2):715-724, 2012.
  26. Gao, W. and W.J. Jusko. Modeling disease progression and rosiglitazone intervention in type 2 diabetic goto-kakizaki rats. Journal of Pharmacology and Experimental Therapeutics 341(3):617-625, 2012.
  27. Gao, W. and W.J. Jusko. Target-mediated pharmacokinetic and pharmacodynamic model of exendin-4 in rats, monkeys, and humans. Drug Metabolism and Disposition 40(5):990-997, 2012.
  28. Gibiansky, L., E. Gibiansky and R. Bauer. Comparison of nonmem 7.2 estimation methods and parallel processing efficiency on a target-mediated drug disposition model. Journal of Pharmacokinetics and Pharmacodynamics 39(1):17-35, 2012.
  29. Giussani, A., T. Janzen, H. Uusijärvi-Lizana, F. Tavola, M. Zankl, M. Sydoff, . . . and M.-C. Cantone. A Compartmental model for biokinetics and dosimetry of 18F-choline in prostate cancer patients. Journal of Nuclear Medicine 53(6):985-993, 2012.
  30. Hall, R. G., M.A. Swancutt, C. Meek, R.D. Leff and T. Gumbo. Ethambutol pharmacokinetic variability is linked to body mass in overweight, obese, and extremely obese people. Antimicrobial Agents and Chemotherapy 56(3):1502-1507, 2012.
  31. Harrison, N. Conference scene: report on the pharmacogenomics and personalized medicine 2011 conference: part 2. Pharmacogenomics 13(3):265-268, 2012.
  32. Hasa, D., B. Perissutti, M.R. Chierotti, R. Gobetto, I. Grabnar, A. Bonifacio, . . .and D. Voinovich. Mechanochemically induced disordered structures of vincamine: the different mediation of two cross-linked polymers. International Journal of Pharmaceutics 436(1-2):41-57, 2012.
  33. Hegde, S.S., O.O. Okusanya, R. Skinner, J.-P. Shaw, G. Obedencio, P.G. Ambrose, . . .and S.M. Bhavnani. Pharmacodynamics of TD-1792, a novel glycopeptide-cephalosporin heterodimer antibiotic used against gram-positive bacteria, in a neutropenic murine thigh model. Antimicrobial Agents and Chemotherapy 56(3):1578-1583, 2012.
  34. Hirsch, E.B. In vitro activity of MK-7655, a novel beta-lactamase inhibitor, in combination with imipenem against carbapenem resistant Gram-negative bacteria. Antimicrobial Agents and Chemotherapy 56(7):3753-3757, 2012.
  35. Hope, W.W. Population pharmacokinetics of voriconazole in adults. Antimicrobial Agents and Chemotherapy 56(1):526-531, 2012.
  36. Hope, W.W., J. Goodwin, T.W. Felton, M. Ellis, and D.A. Stevens. Population pharmacokinetics of conventional and intermittent dosing of liposomal amphotericin B in adults: a first critical step for rational design of innovative regimens. Antimicrobial Agents and Chemotherapy 56(10):5303-5308, 2012.
  37. Hornecker, M. Saturable absorption of sorafenib in patients with solid tumors: a population model. Investigational New Drugs 30(5):1991-2000, 2012.
  38. Housman, S.T., J.S. Pope, J. Russomanno, E. Salerno, E. Shore, J.L. Kuti and D.P. Nicolau. Pulmonary disposition of tedizolid following administration of once-daily oral 200-milligram tedizolid phosphate in healthy adult volunteers. Antimicrobial Agents and Chemotherapy 56(5):2627-2634, 2012.
  39. Howard, S.J., J.M. Lestner, A. Sharp, L. Gregson, J. Slater, J.B. Majithiya, P.A. Warn and W. Hope. Pharmacokinetics and Pharmacodynamics of Posaconazole for Invasive Pulmonary Aspergillosis: Clinical Implications for Antifungal Therapy. Journal of Infectious Diseases 203(9):1324-1332, 2012.
  40. Jarkowski, A., A. Forrest, R.P. Sweeney, W. Tan, B.H. Segal,…and M. Wetzler. Characterization of vancomycin pharmacokinetics in the adult acute myeloid leukemia population. Journal of Oncology Pharmacy Practice 18(1):91-96, 2012.
  41. Jeans, A.R., S.J. Howard, Z. Al-Nakeeb, J. Goodwin, L. Gregson, J.B. Majithiya, . . .and W.W. Hope. Pharmacodynamics of voriconazole in a dynamic in vitro model of invasive pulmonary aspergillosis: implications for in vitro susceptibility breakpoints. Journal of Infectious Diseases 206(3):442-452, 2012.
  42. Jullien, V., B. Blanchet, M. Benyamina, M. Tod, and C. Vinsonneau. Pharmacokinetics of caspofungin in two patients with burn injuries. Antimicrobial Agents and Chemotherapy 56(8):4550-4551, 2012.
  43. Kang, D., K.-S. Bae, B.E. Houk, R.M. Savic, and M.O. Karlsson. Standard error of empirical bayes estimate in NONMEM® VI. Korean Journal of Physiology and Pharmacology 16(2):97-106, 2012.
  44. Kay, B., C.-P. Hsu, J.-F. Lu, Y.-N. Sun, S. Bai, Y. Xin and D. D’Argenio. Intracellular-signaling tumor-regression modeling of the pro-apoptotic receptor agonists dulanermin and conatumumab. Journal of Pharmacokinetics and Pharmacodynamics 39(5):577-590, 2012.
  45. Krzyzanski, W. and J. Perez Ruixo. Lifespan based indirect response models. Journal of Pharmacokinetics and Pharmacodynamics 39(1):109-123, 2012.
  46. Landersdorfer, C.B., J.B. Bulitta, C.M.J. Kirkpatrick, M. Kinzig, U. Holzgrabe, G.L. Drusano, . . .and F. Sörgel. Population pharmacokinetics of piperacillin at two dose levels: influence of nonlinear pharmacokinetics on the pharmacodynamic profile. Antimicrobial Agents and Chemotherapy 56(11):5715-5723, 2012.
  47. Landersdorfer, C.B., Y.-L. He and W.J. Jusko. Mechanism-based population modelling of the effects of vildagliptin on GLP-1, glucose and insulin in patients with type 2 diabetes. British Journal of Clinical Pharmacology 73(3):373-390, 2012.
  48. Landersdorfer, C.B., Y.-L. He and W.J. Jusko. Mechanism-based population pharmacokinetic modelling in diabetes: vildagliptin as a tight binding inhibitor and substrate of dipeptidyl peptidase IV. British Journal of Clinical Pharmacology 73(3):391-401, 2012.
  49. Lecca, P., D. Morpurgo, G. Fantaccini, A. Casagrande, and C. Priami. Inferring biochemical reaction pathways: the case of the gemcitabine pharmacokinetics.BMC Systems Biology 6(1):51, 2012.
  50. Li, P., M. Weiss, and M.S. Roberts. Hepatic interaction between quinidine and digoxin: role of inhibition of sinusoidal Na+/K+ ATPase digoxin binding. European Journal of Pharmaceutical Sciences 47(2):506-511, 2012.
  51. Livermore, J.L., T.W. Felton, J. Abbott, A. Sharp, J. Goodwin, L. Gregson, . . .and W.W. Hope. Pharmacokinetics and pharmacodynamics of anidulafungin for experimental candida endophthalmitis: insights into the utility of echinocandins for treatment of a potentially sight-threatening Infection. Antimicrobial Agents and Chemotherapy 57(1):281-288, 2012.
  52. Lyddon, R., A.J. Dwork, M. Keddache, L.J. Siever and S. Dracheva. Serotonin 2c receptor RNA editing in major depression and suicide. World Journal of Biological Psychiatry 0(0):1-12, 2012.
  53. Mager, D., V. Mody, C. Xu, A. Forrest, W. Lesniak, S. Nigavekar, . . .and L. Balogh. Physiologically based pharmacokinetic model for composite nanodevices: effect of charge and size on in vivo disposition. Pharmaceutical Research 29(0):2534-2542, 2012.
  54. Marathe, A., S. Iyer, Z. Qiu, J. Visich, and D. Mager. Pharmacokinetics and Pharmacodynamics of Anti-BR3 Monoclonal Antibody in Mice. Pharmaceutical Research 29(0):3186-3187, 2012.
  55. McPherson, C., B. Warner, D.A. Hunstad, A. Elward and E.P. Acosta. Oseltamivir dosing in premature infants. Journal of Infectious Diseases 206(6):847-850, 2012.
  56. Meng, S., B. Wu, R. Singh, T. Yin, J.K. Morrow, S. Zhang and M. Hu. SULT1A3-mediated regiospecific 7-O-sulfation of flavonoids in caco-2 cells can be explained by the relevant molecular docking studies. Molecular Pharmaceutics 9(4):862-873, 2012.
  57. Mir, O., R. Coriat, B. Blanchet, J.-P. Durand,…and F. Goldwasser. Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma. PLoS ONE 7(5):e37563, 2012.
  58. Paixão, P., L.F. Gouveia, and J.A.G. Morais. Prediction of the human oral bioavailability by using in vitro and in silico drug related parameters in a physiologically based absorption model. International Journal of Pharmaceutics 429(1-2):84-98, 2012.
  59. Pietanza, M.C., S.M. Gadgeel, A. Dowlati, T.J. Lynch, R. Salgia,…and N.A. Rizvi. Phase II study of the multitargeted tyrosine kinase inhibitor XL647 in patients with non-small-cell lung cancer. Journal of Thoracic Oncology 7(5):856-865, 2012.
  60. Pillay, V., Y.E. Choonara, P. Kumar, V.M.K. Ndesendo and L.C. Toit (2012). Legislative measures for in vitro–in vivo correlations and pharmacokinetic modeling patenting nanomedicines. E. B. Souto, Springer Berlin Heidelberg 0(0):49-96, 2012.
  61. Qaddoumi, I., C.A. Billups, M. Tagen, C.F. Stewart, J. Wu, K. Helton, . . .and M.W. Wilson. Topotecan and vincristine combination is effective against advanced bilateral intraocular retinoblastoma and has manageable toxicity. Cancer 118(22):5663-5670, 2012.
  62. Schmalstieg, A.M., S. Srivastava, S. Belkaya, D. Deshpande, C. Meek, R. Leff, . . .and T. Gumbo. The antibiotic resistance arrow of time: efflux pump induction is a general first step in the evolution of mycobacterial drug resistance. Antimicrobial Agents and Chemotherapy 56(9):4806-4815, 2012.
  63. Schneider, B., G. Kalemkerian, D. Bradley, D. Smith, M. Egorin, S. Daignault, . . .and M. Hussain. Phase I study of vorinostat (suberoylanilide hydroxamic acid, NSC 701852) in combination with docetaxel in patients with advanced and relapsed solid malignancies. Investigational New Drugs 30(1):249-257, 2012.
  64. Shah, D., and A. Betts. Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human. Journal of Pharmacokinetics and Pharmacodynamics 39(1):67-86, 2012.
  65. Sherwin, C.M.T., S.N. Saldaña, R.R. Bies, M.G. Aman and A.A. Vinks. Population pharmacokinetic modeling of risperidone and 9-hydroxyrisperidone to estimate CYP2D6 subpopulations in children and adolescents. Therapeutic Drug Monitoring 34(5):535-544 2012.
  66. Singh, R., M.C. Swick, K.R. Ledesma, Z. Yang, M. Hu, L. Zechiedrich and V.H. Tam. Temporal interplay between efflux pumps and target mutations in development of antibiotic resistance in escherichia coli. Antimicrobial Agents and Chemotherapy 56(4):1680-1685, 2012.
  67. Sukumaran, S., E.-I. Lepist, D. DuBois, R. Almon, W. Jusko. Pharmacokinetic/pharmacodynamic modeling of methylprednisolone effects on iNOS mRNA expression and nitric oxide during LPS-induced inflammation in rats. Pharmaceutical Research 29(8):2060-2069, 2012.
  68. Synold, T., B. Xi, J. Wu, Y. Yen, B. Li, F. Yang, . . .and P. Dervan. Single-dose pharmacokinetic and toxicity analysis of pyrrole–imidazole polyamides in mice. Cancer Chemotherapy and Pharmacology 67(0):617-625, 2012.
  69. Thudium, K.E., S. Ghoshal, G.J. Fetterly, J.P.D. Haese, A.R. Karpf and M. Wetzler. Synergism between clofarabine and decitabine through p53R2: A pharmacodynamic drug–drug interaction modeling. Leukemia Research 36(11):1410-1416, 2012.
  70. Tisdale, J.E., B.R. Overholser, H.A. Wroblewski, K.M. Sowinski, K.Amankwa, S. Borzak, J.R. Kingery,… Enhanced sensitivity to drug-induced QT interval lengthening in patients with heart failure due to left ventricular systolic dysfunction. The Journal of Clinical Pharmacology 52(0):1296-1305, 2012.
  71. Tsuji, B.T., T. Brown, R. Parasrampuria, D.A. Brazeau, A. Forrest, P.A. Kelchlin, . . .and J.B. Bulitta. Front-loaded linezolid regimens result in increased killing and suppression of the accessory gene regulator system of staphylococcus aureus. Antimicrobial Agents and Chemotherapy 56(7):3712-3719, 2012.
  72. Tsuji, B.T., J.B. Bulitta, T. Brown, A. Forrest, P.A. Kelchlin, P.N. Holden, . . .and D. Hanna. Pharmacodynamics of early, high-dose linezolid against vancomycin-resistant enterococci with elevated MICs and pre-existing genetic mutations. Journal of Antimicrobial Chemotherapy 67(9):2182-2190, 2012.
  73. Varatharajan, S., A. Abraham, W. Zhang, R. Shaji, R. Ahmed, A. Abraham, . . .and P. Balasubramanian. Carbonyl reductase 1 expression influences daunorubicin metabolism in acute myeloid leukemia. European Journal of Clinical Pharmacology 68(0):1577-1586, 2012.
  74. Warn, P.A., J. Livermore, S. Howard, T.W. Felton, A. Sharp, L. Gregson, . . .and W.W. Hope. Anidulafungin for neonatal hematogenous candida meningoencephalitis: identification of candidate regimens for humans using a translational pharmacological approach. Antimicrobial Agents and Chemotherapy 56(2):708-714, 2012.
  75. Weiss, M. A model for transit time distributions through organs that accounts for fractal heterogeneity. Journal of Theoretical Biology 301(0):57-61, 2012.
  76. Weiss, M., P. Li, and M.S. Roberts. Estimation of sinusoidal flow heterogeneity in normal and diseased rat livers from tracer dilution data using a fractal model. Journal of Microcirculation 19(0):723-728, 2012.
  77. Weiss, M., P. Sermsappasuk, W. Siegmund. Modeling the kinetics of digoxin absorption. The Journal of Clinical Pharmacology 52(3):381-387, 2012.
  78. Wilhelm, A. J. Population pharmacokinetics of ciclosporin in haematopoietic allogeneic stem cell transplantation with emphasis on limited sampling strategy. British Journal of Clinical Pharmacology 73(4):553-563, 2012.
  79. Wong, H., N.R. Budha, K. West, E. Blackwood, J. Ware, R. Yu, . . .and W.J. Fairbrother. Dogs are more sensitive to antagonists of inhibitor of apoptosis (IAP) proteins than rats and humans: a translational toxicokinetic/toxicodynamic analysis. Toxicological Sciences 130(1): 205-213, 2012.
  80. Wong, H., E.F. Choo, B. Alicke, X. Ding, H. La, E. McNamara, . . .and S.E. Gould. Antitumor activity of targeted and cytotoxic agents in murine subcutaneous tumor models correlates with clinical response.Clinical Cancer Research 18(14):3846-3855, 2012.
  81. Wong, H., L. Vernillet, A. Peterson, J.A. Ware, L. Lee, J.-F. Martini, . . .and J. Prescott. Bridging the gap between preclinical and clinical studies using pharmacokinetic–pharmacodynamic modeling: an analysis of GDC-0973, a MEK inhibitor. Clinical Cancer Research 18(11):3090-3099, 2012.
  82. Yan, X., Y. Chen and W. Krzyzanski. Methods of solving rapid binding target-mediated drug disposition model for two drugs competing for the same receptor. Journal of Pharmacokinetics and Pharmacodynamics 39(5):543-560, 2012.
  83. Zheng, F. and C.-G. Zhan. Modeling of pharmacokinetics of cocaine in human reveals the feasibility for development of enzyme therapies for drugs of abuse. PLoS Comput Biol 8(7):e1002610, 2012.
  84. Zhu, R. The pharmacogenetics of NAT2 enzyme maturation in perinatally HIV exposed infants receiving isoniazid. The Journal of Clinical Pharmacology 52(4):511-519, 2012.